Longitudinal and observational registry-based cohort study of individuals participating in the national digiphysical screening program for Familial Hypercholesterolemia. The information collected in the screening process will be combined in pseudo-anonymous form with data from the National Board of Health and Welfare (registries: Cause of Death, Diagnoses according to International Classification of Diseases (ICD) and Prescribed drugs) and Statistic Sweden (Longitudinal integrated database for health insurance and labour market studies). Primary analysis: association between Familial Hypercholesterolemia and cardiovascular disease. Secondary analysis: efficacy and health economic aspects of digiphysical screening for Familial Hypercholesterolemia.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cardiovascular disease burden in patients with newly diagnosed Familial Hypercholesterolemia
Timeframe: Through study completion, until 2041.
Change in cardiovascular disease burden in patients with diagnosed Familial Hypercholesterolemia
Timeframe: Through study completion, until 2041.
Impact of mutation positive Familial Hypercholesterolemia on cardiovascular disease burden
Timeframe: Through study completion, until 2041.
Comparison of cardiovascular disease burden between patients with diagnosed Familial Hypercholesterolemia and individuals aquitted from the diagnose
Timeframe: Through study completion, until 2041.